Mutant huntingtin protein (mHTT) clearance represents one of the most promising therapeutic strategies for Huntington's disease (HD). The accumulation of mHTT due to expanded CAG repeats in the HTT gene leads to toxic gain-of-function effects, including transcriptional dysregulation, mitochondrial dysfunction, and neuronal death[1]. Various approaches have been developed to enhance mHTT clearance, including antisense oligonucleotides (ASOs), CRISPR-based gene editing, autophagy enhancement, and proteasome modulation.
Huntington's disease is an autosomal dominant neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. The disease results from an expansion of CAG trinucleotide repeats in the HTT gene, encoding a mutant huntingtin protein with an elongated polyglutamine tract. This mutant protein acquires toxic properties that disrupt multiple cellular processes, including transcription, mitochondrial function, protein homeostasis, and synaptic transmission.
The central role of mHTT in disease pathogenesis makes it an attractive therapeutic target. The goal of mHTT-lowering therapies is to reduce the burden of mutant protein in affected neurons, thereby slowing or halting disease progression. This page provides a comprehensive overview of current approaches to mHTT clearance, their mechanisms, clinical development status, and future directions.
The toxic gain-of-function in HD results from multiple mechanisms[2]:
Protein Aggregation: Expanded polyglutamine tracts promote misfolding and aggregation of mHTT. These aggregates:
Transcriptional Dysregulation: mHTT interacts with numerous transcription factors:
Mitochondrial Dysfunction: mHTT directly impairs mitochondrial function[3]:
Axonal Transport Defects: mHTT disrupts vesicle and organelle trafficking:
The quantity of mHTT in the brain correlates with disease severity[4]. Key observations include:
ASOs are short synthetic DNA sequences that bind to mRNA and promote its degradation via RNase H. Several ASO approaches have been advanced for HD:
ASOs work through multiple mechanisms:
Tominersen (RG6042): The leading ASO candidate[5]:
The discontinuation of tominersen was a significant setback but provided valuable insights:
Allele-selective ASOs target only the mutant allele[8]:
SNP-Targeting Strategies:
CAG Repeat Targeting:
CRISPR-Cas9 offers the potential for permanent correction of the HTT mutation:
CRISPRi/dCas9 Systems[9]:
Allele-Specific Editing[10][11]:
Viral vector delivery remains challenging[12][13]:
Emerging Delivery Platforms:
Autophagy (specifically macroautophagy) is the primary cellular mechanism for clearing aggregated proteins[15][16]:
mTOR-Dependent Autophagy:
mTOR-Independent Enhancers[17]:
TFEB (Transcription Factor EB) is a master regulator of lysosomal biogenesis[18]:
Enhancing the recruitment of mHTT to autophagosomes:
The ubiquitin-proteasome system (UPS) handles degradation of soluble misfolded proteins[19]:
Small Molecule Activators[20][21]:
Manipulating ubiquitination machinery:
When should mHTT-lowering therapies be initiated?[22]:
Biomarker Considerations:
The question of whether allele-selective approaches are safer[23]:
How can therapeutic molecules be efficiently delivered to the most affected brain regions:
What biomarkers best predict clinical response to mHTT-lowering[4:1][22:1]:
Should mHTT clearance be combined with other disease-modifying approaches:
Tominersen: Despite trial discontinuation, long-term follow-up data has provided valuable insights into the effects of sustained mHTT lowering[24]:
Gene Therapy Trials[12:1][13:1]:
RNA Targeting:
Polyglutamine-Independent Approaches[25]:
Blood-Brain Barrier Penetration[14:1]:
The cellular protein homeostasis network consists of multiple interconnected systems:
Optimal mHTT clearance likely requires coordinating multiple pathways:
The development of mHTT clearance therapies represents a paradigm shift in neurodegenerative disease treatment. Key considerations include[2:1][22:2]:
Rationale for combining mHTT clearance with:
| Approach | Company | Stage | Mechanism |
|---|---|---|---|
| Tominersen | Roche/Genentech | Discontinued | Non-selective ASO |
| WVE-003 | Wave Life Sciences | Phase 1/2 | Allele-selective ASO |
| PTC-518 | PTC Therapeutics | Phase 1 | HTT-lowering ASO |
| ASO-mediated | Various | Preclinical | Multiple mechanisms |
| AAV-CRISPR | Various | Preclinical | Gene editing |
Mutant huntingtin clearance represents the most direct approach to disease modification in Huntington's disease. Multiple therapeutic modalities are in development, each with distinct advantages and limitations. The lessons learned from tominersen have informed next-generation approaches, including allele-selective ASOs and improved delivery systems. Success will require careful patient selection, robust biomarker monitoring, and potentially combination approaches addressing multiple aspects of mHTT pathology.
The field continues to advance rapidly, with new delivery technologies, more selective therapeutic agents, and improved biomarkers providing hope for effective disease modification in HD.
The Huntington's Disease Collaborative Research Project, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes (1993). 1993. ↩︎
Landles et al. The relationship between mutant huntingtin protein and disease progression (2020). 2020. ↩︎ ↩︎
Smith et al. Mitochondrial dysfunction in Huntington's disease (2023). 2023. ↩︎
Caron et al. Quantifying mutant huntingtin in cerebrospinal fluid for HD trials (2023). 2023. ↩︎ ↩︎
Tabrizi et al. Targeting Huntingtin Expression in Patients with Huntington's Disease (2019). 2019. ↩︎
Ames et al. Next-generation antisense oligonucleotides for Huntington's disease (2024). 2024. ↩︎ ↩︎
Martinez et al. Allele-selective ASO approaches in clinical development (2024). 2024. ↩︎ ↩︎
Liu et al. Allele-selective lowering of mutant HTT using antisense oligonucleotides (2020). 2020. ↩︎
Pulsipher et al. CRISPR-Cas9-mediated gene editing of HTT in mouse models of Huntington's disease (2018). 2018. ↩︎
Shin et al. Allele-specific CRISPR-Cas9 editing of Huntington's disease (2016). 2016. ↩︎
Chen et al. CRISPR base editing for CAG repeat diseases (2022). 2022. ↩︎
Kim et al. AAV-mediated gene therapy for Huntington's disease (2023). 2023. ↩︎ ↩︎
Fox et al. Gene therapy delivery challenges in HD (2024). 2024. ↩︎ ↩︎
Yang et al. Exosome delivery of therapeutic ASOs (2023). 2023. ↩︎ ↩︎
Rubinsztein et al. Autophagy and protein aggregation in neurodegeneration (2019). 2019. ↩︎
Valadas et al. Autophagy modulation in neurodegenerative disease (2023). 2023. ↩︎
Sarkar et al. Small molecules enhancing autophagy as therapeutic agents for Huntington's disease (2019). 2019. ↩︎
Wu et al. TFEB activation as therapeutic strategy in HD (2024). 2024. ↩︎
Kumar et al. Ubiquitin-proteasome system in HD (2023). 2023. ↩︎
Berger et al. Proteasome activation enhances mutant huntingtin clearance (2021). 2021. ↩︎
Hong et al. Small molecule proteasome activators for HD (2024). 2024. ↩︎
Lecouteur et al. Biomarkers for huntingtin-lowering therapy response (2022). 2022. ↩︎ ↩︎ ↩︎
Masellis et al. HTT allele-specific expression in Huntington's disease (2020). 2020. ↩︎
Schulte et al. Long-term effects of huntingtin-lowering therapy (2023). 2023. ↩︎
Zhang et al. Polyglutamine toxicity mechanisms in HD (2024). 2024. ↩︎